Novartis has been riding a med tech wave lately, launching new projects to create digital and patient-monitoring devices. In its latest move, the company is working with tech giant Microsoft to develop an intelligent camera system for multiple sclerosis (MS).
Leadless pacemakers from Medtronic and St. Jude Medical performed well in clinical trials, setting the stage for an exciting race for FDA approval between the two bigwigs. In a sign that the finish line is getting closer, the FDA is convening the experts on its circulatory system devices advisory panel to discuss optimal regulation of the devices.
In a win for Boston Scientific ($BSX), the Centers for Medicare & Medicaid Services backed off its proposal to contraindicate usage of the Watchman left atrial appendage closure device in warfarin patients as a condition for reimbursement under its Coverage with Evidence Development program.
Swiss remote diagnostic monitoring company LifeWatch has secured a clearance from the FDA for its wireless, patch-based vital signs monitoring system. It's expected to be used first in medical facilities such as hospitals and nursing homes, but eventually the company expects to target the ambulatory care market as well.
POPULAR COMMENT THREADS
Illumina said last month that it was "actively recruiting" a CEO for its new liquid biopsy spinoff, Grail, looking for someone with an extensive tech background. Now the company has tapped a former Google exec for the role, charging its new leader with helping Grail develop a screening test for the early detection of cancer.
Stryker announced a tuck-in acquisition, saying it has agreed to acquire all of the assets in Synergetics USA's neurology portfolio, which achieved sales of $31 million in 2015. The move will give the company access to at least two electrosurgical devices that are currently distributed by rival Johnson & Johnson.
Usually in the news due to constant rumors of an impending takeover by Stryker, Smith & Nephew announced that it will distribute precision alignment surgery technology alongside its artificial knee implants under an agreement with Aliso Viejo, CA, startup OrthAlign.
Medtronic signaled its interest in abdominal aortic aneurysm repair last year with the $110 million acquisition of Aptus Endosystems and investment in Arsenal AAA in return for an option to acquire the company. Now Medtronic says the first patient was treated in its trial of the Valiant TAAA Stent Graft System for thoracoabdominal aortic aneurysm.
More than a year after Cerus gained FDA approval--now the American Red Cross has bought into its technology with a multi-year deal for its Intercept Blood System for pathogen reduction in platelets and plasma. It's responsible for about 40% of the U.S. blood products, delivering 1.1 million plasma and 780,000 platelet units last year to almost 2,600 hospitals and transfusion centers.
Regentis Biomaterials has raised a $15 million Series D round from investors led by Chinese biopharma Haisco Pharmaceutical Group. The Israeli cartilage repair company will use the financing to conduct a U.S. pivotal trial of its GelrinC, which is implanted as a liquid and forms into a resorbable implant that is ultimately replaced by newly regenerated cartilage.
From Our Sister Sites
Mylan Chairman Robert Coury knows rejection but also the value of persistence. Four months after being spurned by Perrigo shareholders, he has a $7.2 billion deal to buy Sweden's Meda, a company that two years ago rejected an earlier Mylan proposal.
Regulators in Spain are punishing a Barcelona-based drugmaker for a series of manufacturing shortfalls, recalling all batches produced by the company, Farma Mediterrania, from 2014 to present. The crackdown is the second in as many months by Spanish authorities on local producers.